Bioatla, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
BCAB
Bioatla, INCBioAtla, a clinical-stage biopharmaceutical company, reported substantial net losses and a going concern doubt, leading to a 70% workforce reduction and a formal process to explore strategic options.
NASDAQ
BCAB
Bioatla, INCBioAtla, a clinical-stage biopharmaceutical company, provides an update on its 2024 financial results and ongoing clinical development programs focused on conditionally active biologics (CABs) for solid tumor cancers.
NASDAQ
BCAB
Bioatla, INCBioAtla, Inc. details its common stock structure, preferred stock authorization, and anti-takeover provisions in a recent SEC filing.